Title,URL,Description,Details,ShortDetails,Resource,Type,Identifiers,Db,EntrezUID,Properties
"Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.","/pubmed/31059004","Maiti A, Qi Q, Peng X, Yan L, Takabe K, Hait NC.","Int J Oncol. 2019 May 6. doi: 10.3892/ijo.2019.4796. [Epub ahead of print]","Int J Oncol.  2019","PubMed","citation","PMID:31059004","pubmed","31059004","create date:2019/05/07 | first author:Maiti A",
"DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.","/pubmed/31029033","Shi Y, Jin J, Wang X, Ji W, Guan X.","Neoplasia. 2019 Apr 24;21(6):533-544. doi: 10.1016/j.neo.2019.04.001. [Epub ahead of print]","Neoplasia.  2019","PubMed","citation","PMID:31029033 | PMCID:PMC6484230","pubmed","31029033","create date:2019/04/28 | first author:Shi Y",
"The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.","/pubmed/31014367","Ryan D, Paul BT, Koziol J, ElShamy WM.","Breast Cancer Res. 2019 Apr 24;21(1):53. doi: 10.1186/s13058-019-1131-2.","Breast Cancer Res.  2019","PubMed","citation","PMID:31014367 | PMCID:PMC6480921","pubmed","31014367","create date:2019/04/25 | first author:Ryan D",
"LncRNA NRON downregulates lncRNA snaR and inhibits cancer cell proliferation in triple negative breast cancer (TNBC).","/pubmed/30996114","Niu L, Fan Q, Yan M, Wang L.","Biosci Rep. 2019 Apr 17. pii: BSR20190468. doi: 10.1042/BSR20190468. [Epub ahead of print]","Biosci Rep.  2019","PubMed","citation","PMID:30996114","pubmed","30996114","create date:2019/04/19 | first author:Niu L",
"Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.","/pubmed/30918246","He J, Lee HJ, Saha S, Ruan D, Guo H, Chan CH.","Cell Death Dis. 2019 Mar 28;10(4):285. doi: 10.1038/s41419-019-1512-6.","Cell Death Dis.  2019","PubMed","citation","PMID:30918246 | PMCID:PMC6437220","pubmed","30918246","create date:2019/03/29 | first author:He J",
"Investigation of TNBC in vitro Antiproliferative Effects of Versatile Pirrolo[1,2-a]quinoxaline Compounds.","/pubmed/30915341","Perri M, Aiello F, Cione E, Carullo G, Amendola L, Mazzotta S, Caroleo MC.","Front Mol Biosci. 2019 Mar 12;6:12. doi: 10.3389/fmolb.2019.00012. eCollection 2019.","Front Mol Biosci.  2019","PubMed","citation","PMID:30915341 | PMCID:PMC6423061","pubmed","30915341","create date:2019/03/28 | first author:Perri M",
"Atezolizumab Combo Approved for PD-L1-positive TNBC.","/pubmed/30894361","[No authors listed]","Cancer Discov. 2019 May;9(5):OF2. doi: 10.1158/2159-8290.CD-NB2019-038. Epub 2019 Mar 20.","Cancer Discov.  2019","PubMed","citation","PMID:30894361","pubmed","30894361","create date:2019/03/22",
"EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.","/pubmed/30875891","Giró-Perafita A, Rabionet M, Planas M, Feliu L, Ciurana J, Ruiz-Martínez S, Puig T.","Molecules. 2019 Mar 15;24(6). pii: E1027. doi: 10.3390/molecules24061027.","Molecules.  2019","PubMed","citation","PMID:30875891 | PMCID:PMC6471537","pubmed","30875891","create date:2019/03/17 | first author:Giró-Perafita A",
"Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico.","/pubmed/30867801","Uscanga-Perales GI, Santuario-Facio SK, Sanchez-Dominguez CN, Cardona-Huerta S, Muñoz-Maldonado GE, Ruiz-Flores P, Barcenas-Walls JR, Osuna-Rosales LE, Rojas-Martinez A, Gonzalez-Guerrero JF, Valero-Gomez J, Gomez-Macias GS, Barbosa-Quintana A, Barboza-Quintana O, Garza-Guajardo R, Ortiz-Lopez R.","Oncol Lett. 2019 Mar;17(3):3581-3588. doi: 10.3892/ol.2019.9984. Epub 2019 Jan 29.","Oncol Lett.  2019","PubMed","citation","PMID:30867801 | PMCID:PMC6396222","pubmed","30867801","create date:2019/03/15 | first author:Uscanga-Perales GI",
"The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.","/pubmed/30832411","Ramalingam S, Ramamurthy VP, Gediya LK, Murigi FN, Purushottamachar P, Huang W, Choi EY, Zhang Y, Vasaitis TS, Kane MA, Lapidus RG, Njar VCO.","Cancers (Basel). 2019 Mar 3;11(3). pii: E299. doi: 10.3390/cancers11030299.","Cancers (Basel).  2019","PubMed","citation","PMID:30832411 | PMCID:PMC6468747","pubmed","30832411","create date:2019/03/06 | first author:Ramalingam S",
"36PStructural diversity of the cardenolide calotropin renders it as a targeted therapy for harnessing TNBC progression through tuning nitric oxide (NO) levels.","/pubmed/30810184","El-Layeh RA, Youness RA, Askary H, Abdelmotaal A, Assal RA.","Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz026.007. doi: 10.1093/annonc/mdz026.007. No abstract available. ","Ann Oncol.  2019","PubMed","citation","PMID:30810184","pubmed","30810184","create date:2019/02/28 | first author:El-Layeh RA",
"Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.","/pubmed/30796656","Rice SR, Feigenberg SJ, Hamza M, Molitoris JK, Bentzen SM, Tkaczuk KHR, Rosenblatt PM, Bellavance EC, Nichols EM.","Breast Cancer Res Treat. 2019 Feb 22. doi: 10.1007/s10549-019-05150-x. [Epub ahead of print]","Breast Cancer Res Treat.  2019","PubMed","citation","PMID:30796656","pubmed","30796656","create date:2019/02/24 | first author:Rice SR",
"Genomic and GeneChip expression profiling reveals the inhibitory effects of Amorphophalli Rhizoma in TNBC cells.","/pubmed/30731183","Wu C, Chen M, Zhang Q, Yu L, Zhu J, Gao X.","J Ethnopharmacol. 2019 May 10;235:206-218. doi: 10.1016/j.jep.2019.02.004. Epub 2019 Feb 4.","J Ethnopharmacol.  2019","PubMed","citation","PMID:30731183","pubmed","30731183","create date:2019/02/08 | first author:Wu C",
"Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC.","/pubmed/30659204","Wu L, Meng F, Dong L, Block CJ, Mitchell AV, Wu J, Jang H, Chen W, Polin L, Yang Q, Dou QP, Wu G.","Sci Rep. 2019 Jan 18;9(1):236. doi: 10.1038/s41598-018-35619-6.","Sci Rep.  2019","PubMed","citation","PMID:30659204 | PMCID:PMC6338744","pubmed","30659204","create date:2019/01/20 | first author:Wu L",
"Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis.","/pubmed/30640712","López-Ozuna VM, Hachim IY, Hachim MY, Lebrun JJ, Ali S.","Endocr Relat Cancer. 2019 Jan 1. pii: ERC-18-0523.R1. doi: 10.1530/ERC-18-0523. [Epub ahead of print]","Endocr Relat Cancer.  2019","PubMed","citation","PMID:30640712","pubmed","30640712","create date:2019/01/15 | first author:López-Ozuna VM",
"Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study.","/pubmed/30630526","Yi D, Xu L, Luo J, You X, Huang T, Zi Y, Li X, Wang R, Zhong Z, Tang X, Li A, Shi Y, Rao J, Zhang Y, Sang J.","Hum Genomics. 2019 Jan 10;13(1):4. doi: 10.1186/s40246-018-0186-y.","Hum Genomics.  2019","PubMed","citation","PMID:30630526 | PMCID:PMC6327518","pubmed","30630526","create date:2019/01/12 | first author:Yi D",
"Setting dictates efficacy of pembrolizumab in TNBC.","/pubmed/30573793","Sidaway P.","Nat Rev Clin Oncol. 2019 Feb;16(2):66. doi: 10.1038/s41571-018-0157-1. No abstract available. ","Nat Rev Clin Oncol.  2019","PubMed","citation","PMID:30573793","pubmed","30573793","create date:2018/12/24 | first author:Sidaway P",
"PD-L1 Inhibitor Improves Survival in TNBC.","/pubmed/30464002","[No authors listed]","Cancer Discov. 2019 Jan;9(1):OF5. doi: 10.1158/2159-8290.CD-NB2018-154. Epub 2018 Nov 21.","Cancer Discov.  2019","PubMed","citation","PMID:30464002","pubmed","30464002","create date:2018/11/23",
"TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.","/pubmed/30428522","Camorani S, Fedele M, Zannetti A, Cerchia L.","Pharmaceuticals (Basel). 2018 Nov 13;11(4). pii: E123. doi: 10.3390/ph11040123. Review.","Pharmaceuticals (Basel).  2018","PubMed","citation","PMID:30428522 | PMCID:PMC6316260","pubmed","30428522","create date:2018/11/16 | first author:Camorani S",
"DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.","/pubmed/30419349","Zhang L, Du Y, Xu S, Jiang Y, Yuan C, Zhou L, Ma X, Bai Y, Lu J, Ma J.","Cancer Lett. 2019 Feb 1;442:242-251. doi: 10.1016/j.canlet.2018.11.003. Epub 2018 Nov 9.","Cancer Lett.  2019","PubMed","citation","PMID:30419349","pubmed","30419349","create date:2018/11/13 | first author:Zhang L",
"Benefit in patients with PD-L1-positive TNBC.","/pubmed/30401935","Romero D.","Nat Rev Clin Oncol. 2019 Jan;16(1):6. doi: 10.1038/s41571-018-0127-7. No abstract available. ","Nat Rev Clin Oncol.  2019","PubMed","citation","PMID:30401935","pubmed","30401935","create date:2018/11/08 | first author:Romero D",
"Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC).","/pubmed/30396169","Liu Y, Zhao Y, Wei Z, Tao L, Sheng X, Wang S, Chen J, Ruan J, Liu Z, Cao Y, Shan Y, Wang A, Chen W, Lu Y.","Cell Physiol Biochem. 2018;50(5):1945-1963. doi: 10.1159/000494874. Epub 2018 Nov 5.","Cell Physiol Biochem.  2018","PubMed","citation","PMID:30396169","pubmed","30396169","create date:2018/11/06 | first author:Liu Y",
"Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance.","/pubmed/30367042","Xiong G, Stewart RL, Chen J, Gao T, Scott TL, Samayoa LM, O'Connor K, Lane AN, Xu R.","Nat Commun. 2018 Oct 26;9(1):4456. doi: 10.1038/s41467-018-06893-9.","Nat Commun.  2018","PubMed","citation","PMID:30367042 | PMCID:PMC6203834","pubmed","30367042","create date:2018/10/28 | first author:Xiong G",
"Positive feedback loop between mitochondrial fission and Notch signaling promotes survivin-mediated survival of TNBC cells.","/pubmed/30323195","Chen L, Zhang J, Lyu Z, Chen Y, Ji X, Cao H, Jin M, Zhu J, Yang J, Ling R, Xing J, Ren T, Lyu Y.","Cell Death Dis. 2018 Oct 15;9(11):1050. doi: 10.1038/s41419-018-1083-y.","Cell Death Dis.  2018","PubMed","citation","PMID:30323195 | PMCID:PMC6189045","pubmed","30323195","create date:2018/10/17 | first author:Chen L",
"Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells.","/pubmed/30289427","Huo J, Chen X, Zhang H, Hu Y, Jiang Y, Liu S, Zhang X.","Acta Biochim Biophys Sin (Shanghai). 2018 Nov 1;50(11):1141-1149. doi: 10.1093/abbs/gmy117.","Acta Biochim Biophys Sin (Shanghai).  2018","PubMed","citation","PMID:30289427","pubmed","30289427","create date:2018/10/06 | first author:Huo J",
"PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.","/pubmed/30250159","Kedan A, Verma N, Saroha A, Shreberk-Shaked M, Müller AK, Nair NU, Lev S.","Cell Death Dis. 2018 Sep 24;9(10):985. doi: 10.1038/s41419-018-1005-z.","Cell Death Dis.  2018","PubMed","citation","PMID:30250159 | PMCID:PMC6155151","pubmed","30250159","create date:2018/09/27 | first author:Kedan A",
"ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.","/pubmed/30237308","Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL.","Mol Cancer Ther. 2018 Dec;17(12):2689-2701. doi: 10.1158/1535-7163.MCT-18-0399. Epub 2018 Sep 20.","Mol Cancer Ther.  2018","PubMed","citation","PMID:30237308 | PMCID:PMC6279518","pubmed","30237308","create date:2018/09/22 | first author:Nguyen K",
"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq.","/pubmed/30181541","Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, Specht MC, Bernstein BE, Michor F, Ellisen LW.","Nat Commun. 2018 Sep 4;9(1):3588. doi: 10.1038/s41467-018-06052-0.","Nat Commun.  2018","PubMed","citation","PMID:30181541 | PMCID:PMC6123496","pubmed","30181541","create date:2018/09/06 | first author:Karaayvaz M",
"Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.","/pubmed/30171174","Wilson TR, Udyavar AR, Chang CW, Spoerke JM, Aimi J, Savage HM, Daemen A, O'Shaughnessy JA, Bourgon R, Lackner MR.","Mol Cancer Res. 2019 Jan;17(1):97-108. doi: 10.1158/1541-7786.MCR-18-0619. Epub 2018 Aug 31.","Mol Cancer Res.  2019","PubMed","citation","PMID:30171174","pubmed","30171174","create date:2018/09/02 | first author:Wilson TR",
"Whole exome sequencing of breast cancer (TNBC) cases from India: association of MSH6 and BRIP1 variants with TNBC risk and oxidative DNA damage.","/pubmed/30136158","Aravind Kumar M, Naushad SM, Narasimgu N, Nagaraju Naik S, Kadali S, Shanker U, Lakshmi Narasu M.","Mol Biol Rep. 2018 Oct;45(5):1413-1419. doi: 10.1007/s11033-018-4307-4. Epub 2018 Aug 22.","Mol Biol Rep.  2018","PubMed","citation","PMID:30136158","pubmed","30136158","create date:2018/08/24 | first author:Aravind Kumar M",
"Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).","/pubmed/30040817","Hilton J, Stober C, Mazzarello S, Vandermeer L, Fergusson D, Hutton B, Clemons M.","PLoS One. 2018 Jul 24;13(7):e0199297. doi: 10.1371/journal.pone.0199297. eCollection 2018.","PLoS One.  2018","PubMed","citation","PMID:30040817 | PMCID:PMC6057636","pubmed","30040817","create date:2018/07/25 | first author:Hilton J",
"Leveraging MYC as a therapeutic treatment option for TNBC.","/pubmed/30035166","Carey JPW, Keyomarsi K.","Oncoscience. 2018 Jun 24;5(5-6):137-139. doi: 10.18632/oncoscience.424. eCollection 2018 May. No abstract available. ","Oncoscience.  2018","PubMed","citation","PMID:30035166 | PMCID:PMC6049306","pubmed","30035166","create date:2018/07/24 | first author:Carey JPW",
"Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.","/pubmed/30012592","Ren C, Zhang G, Han F, Fu S, Cao Y, Zhang F, Zhang Q, Meslamani J, Xu Y, Ji D, Cao L, Zhou Q, Cheung KL, Sharma R, Babault N, Yi Z, Zhang W, Walsh MJ, Zeng L, Zhou MM.","Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7949-7954. doi: 10.1073/pnas.1720000115. Epub 2018 Jul 16.","Proc Natl Acad Sci U S A.  2018","PubMed","citation","PMID:30012592 | PMCID:PMC6077712","pubmed","30012592","create date:2018/07/18 | first author:Ren C",
"Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.","/pubmed/29991529","Regan Anderson TM, Ma S, Perez Kerkvliet C, Peng Y, Helle TM, Krutilina RI, Raj GV, Cidlowski JA, Ostrander JH, Schwertfeger KL, Seagroves TN, Lange CA.","Mol Cancer Res. 2018 Nov;16(11):1761-1772. doi: 10.1158/1541-7786.MCR-18-0410. Epub 2018 Jul 10.","Mol Cancer Res.  2018","PubMed","citation","PMID:29991529 | PMCID:PMC6214723","pubmed","29991529","create date:2018/07/12 | first author:Regan Anderson TM",
"Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.","/pubmed/29924958","Han J, Yu J, Dai Y, Li J, Guo M, Song J, Zhou X.","Bosn J Basic Med Sci. 2019 Feb 12;19(1):52-59. doi: 10.17305/bjbms.2018.3399.","Bosn J Basic Med Sci.  2019","PubMed","citation","PMID:29924958 | PMCID:PMC6387672","pubmed","29924958","create date:2018/06/21 | first author:Han J",
"Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.","/pubmed/29901185","Kang DY, Sp N, Kim DH, Joung YH, Lee HG, Park YM, Yang YM.","Int J Oncol. 2018 Aug;53(2):877-885. doi: 10.3892/ijo.2018.4430. Epub 2018 Jun 5.","Int J Oncol.  2018","PubMed","citation","PMID:29901185","pubmed","29901185","create date:2018/06/15 | first author:Kang DY",
"An Immunosuppressive Role for Eya3 in TNBC.","/pubmed/29884726","[No authors listed]","Cancer Discov. 2018 Aug;8(8):OF8. doi: 10.1158/2159-8290.CD-NB2018-072. Epub 2018 Jun 8.","Cancer Discov.  2018","PubMed","citation","PMID:29884726","pubmed","29884726","create date:2018/06/10",
"TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.","/pubmed/29792857","Xu X, Zhang L, He X, Zhang P, Sun C, Xu X, Lu Y, Li F.","Biochem Biophys Res Commun. 2018 Jul 7;502(1):160-165. doi: 10.1016/j.bbrc.2018.05.139. Epub 2018 May 24.","Biochem Biophys Res Commun.  2018","PubMed","citation","PMID:29792857","pubmed","29792857","create date:2018/05/25 | first author:Xu X",
"IMP3 promotes TNBC stem cell property through miRNA-34a regulation.","/pubmed/29771420","Huang QD, Zheng SR, Cai YJ, Chen DL, Shen YY, Lin CQ, Hu XQ, Wang XH, Shi H, Guo GL.","Eur Rev Med Pharmacol Sci. 2018 May;22(9):2688-2696. doi: 10.26355/eurrev_201805_14965.","Eur Rev Med Pharmacol Sci.  2018","PubMed","citation","PMID:29771420","pubmed","29771420","create date:2018/05/18 | first author:Huang QD",
"How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.","/pubmed/29765774","Park JH, Ahn JH, Kim SB.","ESMO Open. 2018 May 3;3(Suppl 1):e000357. doi: 10.1136/esmoopen-2018-000357. eCollection 2018. Review.","ESMO Open.  2018","PubMed","citation","PMID:29765774 | PMCID:PMC5950702","pubmed","29765774","create date:2018/05/17 | first author:Park JH",
"GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells.","/pubmed/29758456","Deng Q, Jiang G, Wu Y, Li J, Liang W, Chen L, Su Q, Li W, Du J, Wong CKC, Chen Z, Wang H.","J Hazard Mater. 2018 Aug 5;355:1-9. doi: 10.1016/j.jhazmat.2018.05.013. Epub 2018 May 8.","J Hazard Mater.  2018","PubMed","citation","PMID:29758456","pubmed","29758456","create date:2018/05/15 | first author:Deng Q",
"Inhibiting PTPN12-Regulated RTKs May Be Therapeutic in TNBC.","/pubmed/29602824","[No authors listed]","Cancer Discov. 2018 May;8(5):530. doi: 10.1158/2159-8290.CD-RW2018-056. Epub 2018 Mar 30.","Cancer Discov.  2018","PubMed","citation","PMID:29602824","pubmed","29602824","create date:2018/04/01",
"The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.","/pubmed/29587820","Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG.","J Exp Clin Cancer Res. 2018 Mar 27;37(1):72. doi: 10.1186/s13046-018-0741-3. No abstract available. ","J Exp Clin Cancer Res.  2018","PubMed","citation","PMID:29587820 | PMCID:PMC5872523","pubmed","29587820","create date:2018/03/29 | first author:Cretella D",
"The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling.","/pubmed/29552303","Faria M, Karami S, Granados-Principal S, Dey P, Verma A, Choi DS, Elemento O, Bawa-Khalfe T, Chang JC, Strom AM, Gustafsson JÅ.","Oncotarget. 2018 Jan 10;9(15):12201-12211. doi: 10.18632/oncotarget.24134. eCollection 2018 Feb 23.","Oncotarget.  2018","PubMed","citation","PMID:29552303 | PMCID:PMC5844739","pubmed","29552303","create date:2018/03/20 | first author:Faria M",
"Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).","/pubmed/29547591","Chen Y, Tang Y, Mao B, Li W, Jin H, Zhang L, Liu Z.","Molecules. 2018 Mar 16;23(3). pii: E678. doi: 10.3390/molecules23030678.","Molecules.  2018","PubMed","citation","PMID:29547591 | PMCID:PMC6017705","pubmed","29547591","create date:2018/03/17 | first author:Chen Y",
"Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.","/pubmed/29453319","Bowers LW, Rossi EL, McDonell SB, Doerstling SS, Khatib SA, Lineberger CG, Albright JE, Tang X, deGraffenried LA, Hursting SD.","Mol Cancer Res. 2018 May;16(5):869-879. doi: 10.1158/1541-7786.MCR-17-0508. Epub 2018 Feb 16.","Mol Cancer Res.  2018","PubMed","citation","PMID:29453319 | PMCID:PMC5967653","pubmed","29453319","create date:2018/02/18 | first author:Bowers LW",
"Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.","/pubmed/29424936","Kwa MJ, Adams S.","Cancer. 2018 May 15;124(10):2086-2103. doi: 10.1002/cncr.31272. Epub 2018 Feb 9. Review.","Cancer.  2018","PubMed","citation","PMID:29424936","pubmed","29424936","create date:2018/02/10 | first author:Kwa MJ",
"First international TNBC conference meeting report.","/pubmed/29417299","Rida P, Ogden A, Ellis IO, Varga Z, Wolff AC, Traina TA, Hatzis C, Palmer JR, Ambrosone CB, Lehmann BD, Nanda R, Montgomery Rice V, Brawley OW, Torres MA, Rakha E, Aneja R.","Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.","Breast Cancer Res Treat.  2018","PubMed","citation","PMID:29417299 | PMCID:PMC5955852","pubmed","29417299","create date:2018/02/09 | first author:Rida P",
"PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?","/pubmed/29387716","Cerbelli B, Pernazza A, Botticelli A, Fortunato L, Monti M, Sciattella P, Campagna D, Mazzuca F, Mauri M, Naso G, Marchetti P, d'Amati G, Costarelli L.","Biomed Res Int. 2017;2017:1750925. doi: 10.1155/2017/1750925. Epub 2017 Dec 14.","Biomed Res Int.  2017","PubMed","citation","PMID:29387716 | PMCID:PMC5745649","pubmed","29387716","create date:2018/02/02 | first author:Cerbelli B",
"STAT3 as a promising chemoresistance biomarker associated with the CD44(+/high)/CD24(-/low)/ALDH(+) BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line.","/pubmed/29352988","Moreira MP, da Conceição Braga L, Cassali GD, Silva LM.","Exp Cell Res. 2018 Feb 15;363(2):283-290. doi: 10.1016/j.yexcr.2018.01.018. Epub 2018 Jan 17.","Exp Cell Res.  2018","PubMed","citation","PMID:29352988","pubmed","29352988","create date:2018/01/22 | first author:Moreira MP",
"I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53.","/pubmed/29334665","Yang M, Dang X, Tan Y, Wang M, Li X, Li G.","Biomed Pharmacother. 2018 Mar;99:220-226. doi: 10.1016/j.biopha.2018.01.063.","Biomed Pharmacother.  2018","PubMed","citation","PMID:29334665","pubmed","29334665","create date:2018/01/16 | first author:Yang M",
"The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).","/pubmed/29301506","Narrandes S, Huang S, Murphy L, Xu W.","BMC Cancer. 2018 Jan 4;18(1):22. doi: 10.1186/s12885-017-3939-4.","BMC Cancer.  2018","PubMed","citation","PMID:29301506 | PMCID:PMC5753474","pubmed","29301506","create date:2018/01/06 | first author:Narrandes S",
"Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): Expression analysis and biological roles research.","/pubmed/29215701","Wang L, Liu D, Wu X, Zeng Y, Li L, Hou Y, Li W, Liu Z.","J Cell Physiol. 2018 Oct;233(10):6603-6612. doi: 10.1002/jcp.26311. Epub 2018 Apr 17.","J Cell Physiol.  2018","PubMed","citation","PMID:29215701","pubmed","29215701","create date:2017/12/08 | first author:Wang L",
"CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.","/pubmed/29159771","Yang M, Li Y, Ruan Y, Lu Y, Lin D, Xie Y, Dong B, Dang Q, Quan C.","Mol Cell Biochem. 2018 Jun;443(1-2):169-180. doi: 10.1007/s11010-017-3221-8. Epub 2017 Nov 20.","Mol Cell Biochem.  2018","PubMed","citation","PMID:29159771","pubmed","29159771","create date:2017/11/22 | first author:Yang M",
"Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).","/pubmed/29120811","Angelini G, Marini C, Iacconi C, Mazzotta D, Moretti M, Picano E, Morganti R.","Clin Imaging. 2018 May - Jun;49:12-16. doi: 10.1016/j.clinimag.2017.10.016. Epub 2017 Oct 27.","Clin Imaging.  2018","PubMed","citation","PMID:29120811","pubmed","29120811","create date:2017/11/10 | first author:Angelini G",
"Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.","/pubmed/28962890","Wu C, Qiu S, Liu P, Ge Y, Gao X.","J Ethnopharmacol. 2018 Jan 30;211:89-100. doi: 10.1016/j.jep.2017.09.033. Epub 2017 Sep 27.","J Ethnopharmacol.  2018","PubMed","citation","PMID:28962890","pubmed","28962890","create date:2017/10/01 | first author:Wu C",
"Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis.","/pubmed/28947965","Jin K, Pandey NB, Popel AS.","Oncotarget. 2017 Jul 21;8(36):60210-60222. doi: 10.18632/oncotarget.19417. eCollection 2017 Sep 1.","Oncotarget.  2017","PubMed","citation","PMID:28947965 | PMCID:PMC5601133","pubmed","28947965","create date:2017/09/28 | first author:Jin K",
"Microarray-based SNP genotyping to identify genetic risk factors of triple-negative breast cancer (TNBC) in South Indian population.","/pubmed/28918577","Aravind Kumar M, Singh V, Naushad SM, Shanker U, Lakshmi Narasu M.","Mol Cell Biochem. 2018 May;442(1-2):1-10. doi: 10.1007/s11010-017-3187-6. Epub 2017 Sep 16.","Mol Cell Biochem.  2018","PubMed","citation","PMID:28918577","pubmed","28918577","create date:2017/09/18 | first author:Aravind Kumar M",
"Kaiso is highly expressed in TNBC tissues of women of African ancestry compared to Caucasian women.","/pubmed/28887687","Bassey-Archibong BI, Hercules SM, Rayner LGA, Skeete DHA, Smith Connell SP, Brain I, Daramola A, Banjo AAF, Byun JS, Gardner K, Dushoff J, Daniel JM.","Cancer Causes Control. 2017 Nov;28(11):1295-1304. doi: 10.1007/s10552-017-0955-2. Epub 2017 Sep 8.","Cancer Causes Control.  2017","PubMed","citation","PMID:28887687 | PMCID:PMC5681979","pubmed","28887687","create date:2017/09/10 | first author:Bassey-Archibong BI",
"Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133(+)/EpCAM(+) phenotype: a promising target for preventing progression of TNBC.","/pubmed/28870198","Brugnoli F, Grassilli S, Lanuti P, Marchisio M, Al-Qassab Y, Vezzali F, Capitani S, Bertagnolo V.","BMC Cancer. 2017 Sep 4;17(1):617. doi: 10.1186/s12885-017-3592-y.","BMC Cancer.  2017","PubMed","citation","PMID:28870198 | PMCID:PMC5584040","pubmed","28870198","create date:2017/09/06 | first author:Brugnoli F",
"Breast cancer: AKT inhibition effective against TNBC.","/pubmed/28857074","Sidaway P.","Nat Rev Clin Oncol. 2017 Nov;14(11):648. doi: 10.1038/nrclinonc.2017.147. Epub 2017 Aug 31. No abstract available. ","Nat Rev Clin Oncol.  2017","PubMed","citation","PMID:28857074","pubmed","28857074","create date:2017/09/01 | first author:Sidaway P",
"Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.","/pubmed/28848054","Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.","Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28.","Cancer Immunol Res.  2017","PubMed","citation","PMID:28848054","pubmed","28848054","create date:2017/08/30 | first author:Brockwell NK",
"Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues.","/pubmed/28832678","Hosokawa Y, Masaki N, Takei S, Horikawa M, Matsushita S, Sugiyama E, Ogura H, Shiiya N, Setou M.","PLoS One. 2017 Aug 23;12(8):e0183724. doi: 10.1371/journal.pone.0183724. eCollection 2017.","PLoS One.  2017","PubMed","citation","PMID:28832678 | PMCID:PMC5568295","pubmed","28832678","create date:2017/08/24 | first author:Hosokawa Y",
"MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.","/pubmed/28764577","Pitner MK, Taliaferro JM, Dalby KN, Bartholomeusz C.","Expert Opin Ther Targets. 2017 Sep;21(9):849-859. doi: 10.1080/14728222.2017.1363183. Epub 2017 Aug 16. Review.","Expert Opin Ther Targets.  2017","PubMed","citation","PMID:28764577","pubmed","28764577","create date:2017/08/03 | first author:Pitner MK",
"STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance.","/pubmed/28729467","Thiagarajan PS, Zheng Q, Bhagrath M, Mulkearns-Hubert EE, Myers MG, Lathia JD, Reizes O.","Endocr Relat Cancer. 2017 Aug;24(8):415-426. doi: 10.1530/ERC-16-0349.","Endocr Relat Cancer.  2017","PubMed","citation","PMID:28729467 | PMCID:PMC5551450","pubmed","28729467","create date:2017/07/22 | first author:Thiagarajan PS",
"Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).","/pubmed/28668293","Wein L, Loi S.","Breast. 2017 Aug;34 Suppl 1:S27-S30. doi: 10.1016/j.breast.2017.06.023. Epub 2017 Jun 28. Review.","Breast.  2017","PubMed","citation","PMID:28668293","pubmed","28668293","create date:2017/07/03 | first author:Wein L",
"Expression of Jagged1/Notch3 Signaling Pathway and their Relationship with the Tumor Angiogenesis in TNBC.","/pubmed/28625320","Xue S, He L, Zhang X, Zhou J, Li F, Wang X.","Arch Med Res. 2017 Feb;48(2):169-179. doi: 10.1016/j.arcmed.2017.03.014.","Arch Med Res.  2017","PubMed","citation","PMID:28625320","pubmed","28625320","create date:2017/06/20 | first author:Xue S",
"The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).","/pubmed/28488168","Tomioka N, Azuma M, Ikarashi M, Yamamoto M, Sato M, Watanabe KI, Yamashiro K, Takahashi M.","Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.","Breast Cancer.  2018","PubMed","citation","PMID:28488168","pubmed","28488168","create date:2017/05/11 | first author:Tomioka N",
"Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).","/pubmed/28383433","Ma F, Li H, Li Y, Ding X, Wang H, Fan Y, Lin C, Qian H, Xu B.","Medicine (Baltimore). 2017 Apr;96(14):e6561. doi: 10.1097/MD.0000000000006561.","Medicine (Baltimore).  2017","PubMed","citation","PMID:28383433 | PMCID:PMC5411217","pubmed","28383433","create date:2017/04/07 | first author:Ma F",
"Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.","/pubmed/28351607","Edupuganti R, Taliaferro JM, Wang Q, Xie X, Cho EJ, Vidhu F, Ren P, Anslyn EV, Bartholomeusz C, Dalby KN.","Bioorg Med Chem. 2017 May 1;25(9):2609-2616. doi: 10.1016/j.bmc.2017.03.018. Epub 2017 Mar 10.","Bioorg Med Chem.  2017","PubMed","citation","PMID:28351607","pubmed","28351607","create date:2017/03/30 | first author:Edupuganti R",
"A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67...","/pubmed/28270498","Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, et al.","Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.","Clin Cancer Res.  2017","PubMed","citation","PMID:28270498 | PMCID:PMC5540799","pubmed","28270498","create date:2017/03/09 | first author:Jovanović B",
"Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).","/pubmed/28270088","Liedtke C, Rody A.","Rev Recent Clin Trials. 2017;12(2):73-80. doi: 10.2174/1574887112666170307095945.","Rev Recent Clin Trials.  2017","PubMed","citation","PMID:28270088","pubmed","28270088","create date:2017/03/09 | first author:Liedtke C",
"Health-related quality of life in Black breast cancer survivors with and without triple-negative breast cancer (TNBC).","/pubmed/28258353","Vadaparampil ST, Christie J, Donovan KA, Kim J, Augusto B, Kasting ML, Holt CL, Ashing K, Halbert CH, Pal T.","Breast Cancer Res Treat. 2017 Jun;163(2):331-342. doi: 10.1007/s10549-017-4173-0. Epub 2017 Mar 3.","Breast Cancer Res Treat.  2017","PubMed","citation","PMID:28258353 | PMCID:PMC5568024","pubmed","28258353","create date:2017/03/05 | first author:Vadaparampil ST",
"Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).","/pubmed/28249200","Godugu C, Doddapaneni R, Singh M.","Colloids Surf B Biointerfaces. 2017 May 1;153:208-219. doi: 10.1016/j.colsurfb.2017.01.038. Epub 2017 Jan 23.","Colloids Surf B Biointerfaces.  2017","PubMed","citation","PMID:28249200 | PMCID:PMC5745346","pubmed","28249200","create date:2017/03/02 | first author:Godugu C",
"TNBC invasion: downstream of STAT3.","/pubmed/28199968","Jackson JG, Lozano G.","Oncotarget. 2017 Mar 28;8(13):20517-20518. doi: 10.18632/oncotarget.15259. No abstract available. ","Oncotarget.  2017","PubMed","citation","PMID:28199968 | PMCID:PMC5400520","pubmed","28199968","create date:2017/02/16 | first author:Jackson JG",
"INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.","/pubmed/28196852","Reed DE, Shokat KM.","Mol Cancer Res. 2017 Jun;15(6):765-775. doi: 10.1158/1541-7786.MCR-16-0183. Epub 2017 Feb 14.","Mol Cancer Res.  2017","PubMed","citation","PMID:28196852 | PMCID:PMC5502826","pubmed","28196852","create date:2017/02/16 | first author:Reed DE",
"SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.","/pubmed/28189679","Feng W, Liu S, Zhu R, Li B, Zhu Z, Yang J, Song C.","Biochem Biophys Res Commun. 2017 Apr 1;485(2):522-528. doi: 10.1016/j.bbrc.2017.02.014. Epub 2017 Feb 9.","Biochem Biophys Res Commun.  2017","PubMed","citation","PMID:28189679","pubmed","28189679","create date:2017/02/13 | first author:Feng W",
"Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia.","/pubmed/28168712","Alcantara VS, Lim GH, Lim SH, Sultana R, Lee JA.","J Surg Oncol. 2017 Apr;115(5):523-537. doi: 10.1002/jso.24559. Epub 2017 Feb 7.","J Surg Oncol.  2017","PubMed","citation","PMID:28168712","pubmed","28168712","create date:2017/02/09 | first author:Alcantara VS",
"Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).","/pubmed/28141839","Qian XL, Zhang J, Li PZ, Lang RG, Li WD, Sun H, Liu FF, Guo XJ, Gu F, Fu L.","PLoS One. 2017 Jan 31;12(1):e0171169. doi: 10.1371/journal.pone.0171169. eCollection 2017.","PLoS One.  2017","PubMed","citation","PMID:28141839 | PMCID:PMC5283743","pubmed","28141839","create date:2017/02/01 | first author:Qian XL",
"Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue.","/pubmed/28039356","Snowden E, Porter W, Hahn F, Ferguson M, Tong F, Parker JS, Middlebrook A, Ghanekar S, Dillmore WS, Blaesius R.","Mol Cancer Res. 2017 Apr;15(4):429-438. doi: 10.1158/1541-7786.MCR-16-0286-T. Epub 2016 Dec 30.","Mol Cancer Res.  2017","PubMed","citation","PMID:28039356","pubmed","28039356","create date:2017/01/01 | first author:Snowden E",
"Liquid biopsy testing in monitoring TNBC.","/pubmed/30047683","Song PY.","MLO Med Lab Obs. 2017 Jan;49(1):26. No abstract available. ","MLO Med Lab Obs.  2017","PubMed","citation","PMID:30047683","pubmed","30047683","create date:2017/01/01 | first author:Song PY",
"Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance.","/pubmed/27959276","Das S.","Med Hypotheses. 2016 Nov;96:5-8. doi: 10.1016/j.mehy.2016.09.004. Epub 2016 Sep 15.","Med Hypotheses.  2016","PubMed","citation","PMID:27959276","pubmed","27959276","create date:2016/12/14 | first author:Das S",
"Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.","/pubmed/27793840","Verma N, Müller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, Holtrich U, Lev S.","Cancer Res. 2017 Jan 1;77(1):86-99. doi: 10.1158/0008-5472.CAN-16-1797. Epub 2016 Oct 28.","Cancer Res.  2017","PubMed","citation","PMID:27793840","pubmed","27793840","create date:2016/10/30 | first author:Verma N",
"Breast cancer molecular subtypes: from TNBC to QNBC.","/pubmed/27725895","Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P.","Am J Cancer Res. 2016 Sep 1;6(9):1864-1872. eCollection 2016. Review.","Am J Cancer Res.  2016","PubMed","citation","PMID:27725895 | PMCID:PMC5043099","pubmed","27725895","create date:2016/10/12 | first author:Hon JD",
"Bursts of Chromosome Changes Drive TNBC.","/pubmed/27599500","[No authors listed]","Cancer Discov. 2016 Oct;6(10):1075. Epub 2016 Sep 6.","Cancer Discov.  2016","PubMed","citation","PMID:27599500","pubmed","27599500","create date:2016/09/08",
"Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.","/pubmed/27561099","Dai D, Chen B, Tang H, Wang B, Zhao Z, Xie X, Wei W.","PLoS One. 2016 Aug 25;11(8):e0161902. doi: 10.1371/journal.pone.0161902. eCollection 2016.","PLoS One.  2016","PubMed","citation","PMID:27561099 | PMCID:PMC4999206","pubmed","27561099","create date:2016/08/26 | first author:Dai D",
"The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.","/pubmed/27545642","Kim JY, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH.","Sci Rep. 2016 Aug 22;6:31804. doi: 10.1038/srep31804.","Sci Rep.  2016","PubMed","citation","PMID:27545642 | PMCID:PMC4992884","pubmed","27545642","create date:2016/08/23 | first author:Kim JY",
"IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.","/pubmed/27462789","Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J.","Oncotarget. 2016 Aug 16;7(33):53350-53361. doi: 10.18632/oncotarget.10804.","Oncotarget.  2016","PubMed","citation","PMID:27462789 | PMCID:PMC5288192","pubmed","27462789","create date:2016/07/28 | first author:Merrouche Y",
"Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.","/pubmed/27401651","Kim S, Park HS, Kim JY, Ryu J, Park S, Kim SI.","Yonsei Med J. 2016 Sep;57(5):1192-8. doi: 10.3349/ymj.2016.57.5.1192.","Yonsei Med J.  2016","PubMed","citation","PMID:27401651 | PMCID:PMC4960386","pubmed","27401651","create date:2016/07/13 | first author:Kim S",
"Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women.","/pubmed/27386241","Prasad S, Efird JT, James SE, Walker PR, Zagar TM, Biswas T.","Springerplus. 2016 Jun 17;5(1):756. doi: 10.1186/s40064-016-2444-6. eCollection 2016.","Springerplus.  2016","PubMed","citation","PMID:27386241 | PMCID:PMC4912515","pubmed","27386241","create date:2016/07/08 | first author:Prasad S",
"How successful is NST in increasing breast-conserving surgery rates in TNBC patients?","/pubmed/27337767","Ollila DW, Golshan M, Boughey JC.","Bull Am Coll Surg. 2016 Apr;101(4):40-2. No abstract available. ","Bull Am Coll Surg.  2016","PubMed","citation","PMID:27337767","pubmed","27337767","create date:2016/06/25 | first author:Ollila DW",
"The length of the bridging chain in ansa-metallocenes influences their antiproliferative activity against triple negative breast cancer cells (TNBC).","/pubmed/27276499","Beauperin M, Top S, Richard MA, Plażuk D, Pigeon P, Toma S, Poláčková V, Jaouen G.","Dalton Trans. 2016 Aug 16;45(33):13126-34. doi: 10.1039/c6dt01640e.","Dalton Trans.  2016","PubMed","citation","PMID:27276499","pubmed","27276499","create date:2016/06/09 | first author:Beauperin M",
"Targeting the untargetable? Nodal expression in TNBC.","/pubmed/27027858","Young ED, Welch DR.","Cell Cycle. 2016 Jun 2;15(11):1400. doi: 10.1080/15384101.2016.1166816. Epub 2016 Mar 30. No abstract available. ","Cell Cycle.  2016","PubMed","citation","PMID:27027858 | PMCID:PMC4934075","pubmed","27027858","create date:2016/03/31 | first author:Young ED",
"Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.","/pubmed/26988771","Biswas T, Efird JT, Prasad S, James SE, Walker PR, Zagar TM.","Clin Breast Cancer. 2016 Jun;16(3):212-6. doi: 10.1016/j.clbc.2016.02.004. Epub 2016 Feb 13.","Clin Breast Cancer.  2016","PubMed","citation","PMID:26988771","pubmed","26988771","create date:2016/03/19 | first author:Biswas T",
"Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?","/pubmed/26842691","Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, Krishnani N.","World J Surg. 2016 Jun;40(6):1362-72. doi: 10.1007/s00268-016-3422-4.","World J Surg.  2016","PubMed","citation","PMID:26842691","pubmed","26842691","create date:2016/02/05 | first author:Agarwal G",
"Chemotherapy with ceramide in TNBC.","/pubmed/26682260","Legembre P, Micheau O, Ségui B.","Oncoscience. 2015 Aug 21;2(10):817-8. eCollection 2015. No abstract available. ","Oncoscience.  2015","PubMed","citation","PMID:26682260 | PMCID:PMC4671935","pubmed","26682260","create date:2015/12/19 | first author:Legembre P",
"The fate of chemoresistance in triple negative breast cancer (TNBC).","/pubmed/26676166","O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A.","BBA Clin. 2015 Mar 12;3:257-75. doi: 10.1016/j.bbacli.2015.03.003. eCollection 2015 Jun. Review.","BBA Clin.  2015","PubMed","citation","PMID:26676166 | PMCID:PMC4661576","pubmed","26676166","create date:2015/12/18 | first author:O'Reilly EA",
"Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.","/pubmed/26432786","Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF.","Clin Cancer Res. 2016 Feb 15;22(4):923-34. doi: 10.1158/1078-0432.CCR-15-0187. Epub 2015 Oct 2.","Clin Cancer Res.  2016","PubMed","citation","PMID:26432786 | PMCID:PMC5500174","pubmed","26432786","create date:2015/10/04 | first author:Sameni M",
"Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).","/pubmed/26405612","Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS.","Oncoimmunology. 2015 Jul 27;4(9):e985930. eCollection 2015 Sep.","Oncoimmunology.  2015","PubMed","citation","PMID:26405612 | PMCID:PMC4570112","pubmed","26405612","create date:2015/09/26 | first author:Adams S",
"Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).","/pubmed/26350593","Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT.","Vaccines (Basel). 2015 Jul 6;3(3):519-43. doi: 10.3390/vaccines3030519.","Vaccines (Basel).  2015","PubMed","citation","PMID:26350593 | PMCID:PMC4586465","pubmed","26350593","create date:2015/09/10 | first author:Overholser J",
"Cripto-1 in TNBC.","/pubmed/26298547","Castro NP, Salomon DS.","Aging (Albany NY). 2015 Aug;7(8):515-6. No abstract available. ","Aging (Albany NY).  2015","PubMed","citation","PMID:26298547 | PMCID:PMC4586090","pubmed","26298547","create date:2015/08/25 | first author:Castro NP",
"Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.","/pubmed/26209610","Campone M, Valo I, Jézéquel P, Moreau M, Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O, Guette C.","Mol Cell Proteomics. 2015 Nov;14(11):2936-46. doi: 10.1074/mcp.M115.048967. Epub 2015 Jul 24.","Mol Cell Proteomics.  2015","PubMed","citation","PMID:26209610 | PMCID:PMC4638037","pubmed","26209610","create date:2015/07/26 | first author:Campone M",
"Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.","/pubmed/26135303","Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G, Adamo V.","PLoS One. 2015 Jul 2;10(7):e0132647. doi: 10.1371/journal.pone.0132647. eCollection 2015. No abstract available. ","PLoS One.  2015","PubMed","citation","PMID:26135303 | PMCID:PMC4489771","pubmed","26135303","create date:2015/07/03 | first author:Ricciardi GR",
"Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.","/pubmed/26051240","Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA.","Clin Breast Cancer. 2015 Dec;15(6):473-481.e3. doi: 10.1016/j.clbc.2015.04.008. Epub 2015 Apr 28.","Clin Breast Cancer.  2015","PubMed","citation","PMID:26051240","pubmed","26051240","create date:2015/06/09 | first author:Millis SZ",
"Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.","/pubmed/26039245","Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G, Adamo V.","PLoS One. 2015 Jun 3;10(6):e0128368. doi: 10.1371/journal.pone.0128368. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0132647. ","PLoS One.  2015","PubMed","citation","PMID:26039245 | PMCID:PMC4454487","pubmed","26039245","create date:2015/06/04 | first author:Ricciardi GR",
"MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.","/pubmed/25943633","Ren YQ, Fu F, Han J.","Med Sci Monit. 2015 May 6;21:1297-303. doi: 10.12659/MSM.893974.","Med Sci Monit.  2015","PubMed","citation","PMID:25943633 | PMCID:PMC4548742","pubmed","25943633","create date:2015/05/07 | first author:Ren YQ",
"Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via Suppressing MMP2/9 by Blocking NF-κB and ERK/MAPK Signaling Pathways.","/pubmed/25927362","Liu Y, Zhu P, Wang Y, Wei Z, Tao L, Zhu Z, Sheng X, Wang S, Ruan J, Liu Z, Cao Y, Shan Y, Sun L, Wang A, Chen W, Lu Y.","PLoS One. 2015 Apr 30;10(4):e0123781. doi: 10.1371/journal.pone.0123781. eCollection 2015.","PLoS One.  2015","PubMed","citation","PMID:25927362 | PMCID:PMC4415928","pubmed","25927362","create date:2015/05/01 | first author:Liu Y",
"Immunotherapy Slows TNBC Progression.","/pubmed/25898834","[No authors listed]","Cancer Discov. 2015 Jun;5(6):570. doi: 10.1158/2159-8290.CD-NB2015-059. Epub 2015 Apr 21.","Cancer Discov.  2015","PubMed","citation","PMID:25898834","pubmed","25898834","create date:2015/04/23",
"The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.","/pubmed/25857298","Tzeng HE, Yang L, Chen K, Wang Y, Liu YR, Pan SL, Gaur S, Hu S, Yen Y.","Oncotarget. 2015 May 10;6(13):11061-73.","Oncotarget.  2015","PubMed","citation","PMID:25857298 | PMCID:PMC4484439","pubmed","25857298","create date:2015/04/11 | first author:Tzeng HE",
"PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells.","/pubmed/25796184","Shin M, Lee KE, Yang EG, Jeon H, Song HK.","FEBS Lett. 2015 Apr 13;589(9):1033-9. doi: 10.1016/j.febslet.2015.03.009. Epub 2015 Mar 18.","FEBS Lett.  2015","PubMed","citation","PMID:25796184","pubmed","25796184","create date:2015/03/23 | first author:Shin M",
"Endophilin A2 Promotes TNBC Cell Invasion and Tumor Metastasis.","/pubmed/25784716","Baldassarre T, Watt K, Truesdell P, Meens J, Schneider MM, Sengupta SK, Craig AW.","Mol Cancer Res. 2015 Jun;13(6):1044-55. doi: 10.1158/1541-7786.MCR-14-0573. Epub 2015 Mar 17.","Mol Cancer Res.  2015","PubMed","citation","PMID:25784716","pubmed","25784716","create date:2015/03/19 | first author:Baldassarre T",
"Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.","/pubmed/25726929","Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM.","Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7.","Eur J Immunol.  2015","PubMed","citation","PMID:25726929","pubmed","25726929","create date:2015/03/03 | first author:Roberti MP",
"GHRH-antagonists in TNBC.","/pubmed/25655918","Engel JB.","Oncotarget. 2015 Feb 10;6(4):1898-9. No abstract available. ","Oncotarget.  2015","PubMed","citation","PMID:25655918 | PMCID:PMC4385824","pubmed","25655918","create date:2015/02/07 | first author:Engel JB",
"Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.","/pubmed/25342642","Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, Teulé A, Fachal L, Martínez B, González-Sarmiento R, Cruz-Hernández JJ, Chirivella I, Garcés V, Garre P, Romero A, Caldés T, Díaz-Rubio E, de la Hoya M.","Breast Cancer Res Treat. 2014 Nov;148(2):415-21. doi: 10.1007/s10549-014-3167-4. Epub 2014 Oct 24.","Breast Cancer Res Treat.  2014","PubMed","citation","PMID:25342642","pubmed","25342642","create date:2014/10/25 | first author:Zugazagoitia J",
"Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.","/pubmed/25341922","Shin M, Yang EG, Song HK, Jeon H.","BMB Rep. 2015 Jun;48(6):342-7.","BMB Rep.  2015","PubMed","citation","PMID:25341922 | PMCID:PMC4578621","pubmed","25341922","create date:2014/10/25 | first author:Shin M",
"Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).","/pubmed/25293576","Kwok CW, Treeck O, Buchholz S, Seitz S, Ortmann O, Engel JB.","Target Oncol. 2015 Sep;10(3):365-73. doi: 10.1007/s11523-014-0340-y. Epub 2014 Oct 9.","Target Oncol.  2015","PubMed","citation","PMID:25293576","pubmed","25293576","create date:2014/10/09 | first author:Kwok CW",
"The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.","/pubmed/25276378","Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J.","J Thorac Dis. 2014 Sep;6(9):1329-35. doi: 10.3978/j.issn.2072-1439.2014.08.13. Review.","J Thorac Dis.  2014","PubMed","citation","PMID:25276378 | PMCID:PMC4178098","pubmed","25276378","create date:2014/10/03 | first author:Jiao Q",
"Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.","/pubmed/25239934","Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG.","Mol Cancer Ther. 2014 Nov;13(11):2688-705. doi: 10.1158/1535-7163.MCT-14-0346. Epub 2014 Sep 19.","Mol Cancer Ther.  2014","PubMed","citation","PMID:25239934 | PMCID:PMC4276724","pubmed","25239934","create date:2014/09/23 | first author:Zhou H",
"Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).","/pubmed/25130168","Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B.","Cancer Lett. 2014 Oct 28;353(2):153-9. doi: 10.1016/j.canlet.2014.06.022. Epub 2014 Aug 14.","Cancer Lett.  2014","PubMed","citation","PMID:25130168","pubmed","25130168","create date:2014/08/19 | first author:Ma F",
"TNBC vs non-TNBC: A retrospective review of differences in mean age, family history, smoking history, and stage at diagnosis.","/pubmed/25003567","Tariq K, Farhangi A, Rana F.","Clin Adv Hematol Oncol. 2014 Jun;12(6):377-81. Review.","Clin Adv Hematol Oncol.  2014","PubMed","citation","PMID:25003567","pubmed","25003567","create date:2014/07/09 | first author:Tariq K",
"Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?","/pubmed/24857120","Moran MS.","Am Soc Clin Oncol Educ Book. 2014:e32-6. doi: 10.14694/EdBook_AM.2014.34.e32. Review.","Am Soc Clin Oncol Educ Book.  2014","PubMed","citation","PMID:24857120","pubmed","24857120","create date:2014/05/27 | first author:Moran MS",
"Breast cancer: TNBC: can we treat the untargetable?","/pubmed/24840078","Hutchinson L.","Nat Rev Clin Oncol. 2014 Jul;11(7):379. doi: 10.1038/nrclinonc.2014.88. Epub 2014 May 20. No abstract available. ","Nat Rev Clin Oncol.  2014","PubMed","citation","PMID:24840078","pubmed","24840078","create date:2014/05/21 | first author:Hutchinson L",
"A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).","/pubmed/24667715","Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M; CT4002 study group..","Ann Oncol. 2014 Apr;25(4):824-31. doi: 10.1093/annonc/mdu025.","Ann Oncol.  2014","PubMed","citation","PMID:24667715","pubmed","24667715","create date:2014/03/29 | first author:Awada A",
"TNBC vs. Non-TNBC: A Five-Year Retrospective Review of Differences in Mean Age, Family History, Smoking History and Stage at Diagnosis at an Inner City University Program.","/pubmed/29147364","Tariq K, Rana F.","World J Oncol. 2013 Dec;4(6):241-247. doi: 10.4021/wjon738w. Epub 2014 Jan 16.","World J Oncol.  2013","PubMed","citation","PMID:29147364 | PMCID:PMC5649849","pubmed","29147364","create date:2013/12/01 | first author:Tariq K",
"Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.","/pubmed/24233638","Zhang M, Zhang X, Zhao S, Wang Y, Di W, Zhao G, Yang M, Zhang Q.","Target Oncol. 2014 Dec;9(4):349-57.","Target Oncol.  2014","PubMed","citation","PMID:24233638","pubmed","24233638","create date:2013/11/16 | first author:Zhang M",
"BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.","/pubmed/24026861","Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J.","Breast Cancer Res Treat. 2013 Sep;141(2):205-12. doi: 10.1007/s10549-013-2693-9. Epub 2013 Sep 13.","Breast Cancer Res Treat.  2013","PubMed","citation","PMID:24026861","pubmed","24026861","create date:2013/09/13 | first author:Ignatov T",
"Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.","/pubmed/24004841","Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M.","BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.","BMC Cancer.  2013","PubMed","citation","PMID:24004841 | PMCID:PMC3849986","pubmed","24004841","create date:2013/09/06 | first author:Wiese DA",
"Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).","/pubmed/23982851","Andrés R, Pajares I, Balmaña J, Llort G, Ramón Y Cajal T, Chirivella I, Aguirre E, Robles L, Lastra E, Pérez-Segura P, Bosch N, Yagüe C, Lerma E, Godino J, Miramar MD, Moros M, Astier P, Saez B, Vidal MJ, Arcusa A, Ramón y Cajal S, Calvo MT, et al.","Clin Transl Oncol. 2014 Mar;16(3):280-4. doi: 10.1007/s12094-013-1070-9. Epub 2013 Aug 27.","Clin Transl Oncol.  2014","PubMed","citation","PMID:23982851","pubmed","23982851","create date:2013/08/29 | first author:Andrés R",
"Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.","/pubmed/23975317","Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E.","Ann Surg Oncol. 2013 Oct;20(10):3254-8. doi: 10.1245/s10434-013-3205-1. Epub 2013 Aug 22.","Ann Surg Oncol.  2013","PubMed","citation","PMID:23975317","pubmed","23975317","create date:2013/08/27 | first author:Greenup R",
"Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.","/pubmed/23973711","Park YH, Jung HH, Ahn JS, Im YH.","Biochem Biophys Res Commun. 2013 Sep 20;439(2):275-9. doi: 10.1016/j.bbrc.2013.08.043. Epub 2013 Aug 21.","Biochem Biophys Res Commun.  2013","PubMed","citation","PMID:23973711","pubmed","23973711","create date:2013/08/27 | first author:Park YH",
"Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.","/pubmed/23908177","Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY.","Ann Oncol. 2013 Nov;24(11):2801-7. doi: 10.1093/annonc/mdt277. Epub 2013 Aug 1.","Ann Oncol.  2013","PubMed","citation","PMID:23908177","pubmed","23908177","create date:2013/08/03 | first author:Abdel-Fatah TM",
"Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.","/pubmed/23886182","Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J.","Asian Pac J Cancer Prev. 2013;14(6):3779-84.","Asian Pac J Cancer Prev.  2013","PubMed","citation","PMID:23886182","pubmed","23886182","create date:2013/07/28 | first author:Li CY",
"Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.","/pubmed/23828443","Engel JB, Honig A, Kapp M, Hahne JC, Meyer SR, Dietl J, Segerer SE.","Arch Gynecol Obstet. 2014 Jan;289(1):141-7. doi: 10.1007/s00404-013-2922-9. Epub 2013 Jul 5.","Arch Gynecol Obstet.  2014","PubMed","citation","PMID:23828443","pubmed","23828443","create date:2013/07/06 | first author:Engel JB",
"Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.","/pubmed/23776059","Brouxhon SM, Kyrkanides S, Teng X, O'Banion MK, Clarke R, Byers S, Ma L.","Mol Carcinog. 2014 Nov;53(11):893-906. doi: 10.1002/mc.22048. Epub 2013 Jun 18.","Mol Carcinog.  2014","PubMed","citation","PMID:23776059 | PMCID:PMC4477712","pubmed","23776059","create date:2013/06/19 | first author:Brouxhon SM",
"RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women.","/pubmed/23625599","Smolarz B, Zadrożny M, Duda-Szymańska J, Makowska M, Samulak D, Michalska MM, Mojs E, Bryś M, Forma E, Romanowicz-Makowska H.","Pol J Pathol. 2013 Apr;64(1):39-43.","Pol J Pathol.  2013","PubMed","citation","PMID:23625599","pubmed","23625599","create date:2013/04/30 | first author:Smolarz B",
"High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients.","/pubmed/23263825","Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu S, Zhang X, Liu Y, Song Y, Liu L, Zhang Q.","Med Oncol. 2013 Mar;30(1):335. doi: 10.1007/s12032-012-0335-4. Epub 2012 Dec 22.","Med Oncol.  2013","PubMed","citation","PMID:23263825 | PMCID:PMC4059361","pubmed","23263825","create date:2012/12/25 | first author:Zhao S",
"Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.","/pubmed/23250547","Oprea-Ilies G, Haus E, Sackett-Lundeen L, Liu Y, McLendon L, Busch R, Adams A, Cohen C.","Breast Cancer Res Treat. 2013 Feb;137(3):677-87. doi: 10.1007/s10549-012-2371-3. Epub 2012 Dec 19.","Breast Cancer Res Treat.  2013","PubMed","citation","PMID:23250547 | PMCID:PMC3552359","pubmed","23250547","create date:2012/12/20 | first author:Oprea-Ilies G",
"Neoadjuvant treatments for triple-negative breast cancer (TNBC).","/pubmed/23012300","von Minckwitz G, Martin M.","Ann Oncol. 2012 Aug;23 Suppl 6:vi35-9. Review.","Ann Oncol.  2012","PubMed","citation","PMID:23012300","pubmed","23012300","create date:2012/10/04 | first author:von Minckwitz G",
"Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH).","/pubmed/25961354","Buchholz S, Seitz S, Engel JB, Montero A, Ortmann O, Perez R, Block NL, Schally AV.","Horm Mol Biol Clin Investig. 2012 Apr 1;9(1):87-94. doi: 10.1515/hmbci-2011-0002.","Horm Mol Biol Clin Investig.  2012","PubMed","citation","PMID:25961354","pubmed","25961354","create date:2012/04/01 | first author:Buchholz S",
"A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease.","/pubmed/22452810","Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A.","BMC Cancer. 2012 Mar 27;12:120. doi: 10.1186/1471-2407-12-120.","BMC Cancer.  2012","PubMed","citation","PMID:22452810 | PMCID:PMC3340297","pubmed","22452810","create date:2012/03/29 | first author:Kaur P",
"Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).","/pubmed/21170648","Cho EY, Chang MH, Choi YL, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH.","Cancer Chemother Pharmacol. 2011 Sep;68(3):753-61. doi: 10.1007/s00280-010-1548-x. Epub 2010 Dec 18.","Cancer Chemother Pharmacol.  2011","PubMed","citation","PMID:21170648","pubmed","21170648","create date:2010/12/21 | first author:Cho EY",
"Treatment of triple negative breast cancer (TNBC): current options and future perspectives.","/pubmed/21129616","De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S.","Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6. doi: 10.1016/S0305-7372(10)70025-6. Review.","Cancer Treat Rev.  2010","PubMed","citation","PMID:21129616","pubmed","21129616","create date:2010/12/07 | first author:De Laurentiis M",
